quietapine in bipolar depression

Bolder I and Bolder II (BipOLar DEpRession) are 8-week, multicenter, double-blind, randomized, fixed-dose, placebo-controlled studies for quetiapine monotherapy in the treatment of bipolar depression. Data from Bolder I, published last year, have indicated a robust effect of quetiapine monotherapy in the treatment of bipolar depression as measured by decreases in the Montgomery Asberg Depression Rating Scale (MADRS). Data from Bolder II show strikingly similar results and further support a role for quetiapine as a first-line treatment for depression in bipolar patients.For quetiapine, sedation or somnolence, mostly within the first week of treatment, is the most common adverse event, leading to treatment dropout.This side effect may be used clinically for specific patient populations, such as in the treatment of patients with anxiety or agitation